Thomas K. Equels - 16 Mar 2026 Form 4 Insider Report for AIM ImmunoTech Inc. (AIM)

Reporting relationship: CEO & President, Director
Issuer ticker: AIM
Reported as of: 16 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Mar 2026, 17:30:41 UTC
Prior SEC filing: 10 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Thomas K Equels

Key filing fact

Thomas K. Equels filed Form 4 for AIM ImmunoTech Inc. (AIM) on 16 Mar 2026.

Key facts

This page summarizes Thomas K. Equels's Form 4 filing for AIM ImmunoTech Inc. (AIM).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 16 Mar 2026, 17:30.

Change

Previous filing in this sequence was filed on 10 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001450324 Primary reporting owner

Equels Thomas K

Relationship: CEO & President, Director
Address: 2117 SOUTHWEST HIGHWAY 484, OCALA,
Signature: /s/ Thomas K Equels
Signature date: 16 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AIM transaction

Common stock

Conversion of derivative security

Transaction value
Shares: +25,000
Change %: +64%
Price: $0.000000^*
Shares after: 63,922
Date: 12 Mar 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AIM transaction Derivative

Series G Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -25
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 12 Mar 2026
Ownership: Direct
Underlying class: common stock
Underlying amount: 25,000
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Preferred shares are convertible into common stock at a rate of 1,000 shares of common stock per whole perferred share, effectively $1.00 per share of common stock.

Footnote F2

None